ʻIkepili Lapaʻau Mua no Allogeneic BCMA CAR-T CT0596, e hōʻike ana i ka palekana maikaʻi a me ka pono

Ma ka lā 12 o Mei, 2025, hoʻolaha ʻo CARsgen i ka ʻikepili lapaʻau mua no CT0596, kahi CAR-T allogeneic BCMA-targeted i hoʻomohala ʻia me ka hoʻohana ʻana i ka paepae THANK-u Plus™. Ke loiloi ʻia nei ʻo CT0596 i loko o kahi noiʻi lapaʻau mua no ka relapsed/refractory multiple myeloma (R/R MM) a i ʻole ka relapsed/refractory plasma cell leukemia (R/R PCL) e loiloi i kona palekana, a me ka pono mua.

Ma ka lā 6 o Mei, 2025, ua kākau inoa ʻia he 8 mau maʻi me R/R MM i loaʻa ma ka liʻiliʻi he ʻekolu mau laina lapaʻau ma mua a ua hoʻokomo ʻia me CT0596 ma hope o ka lymphodepletion me ka regimen FC (fludarabine 22.5-30 mg/m² a me cyclophosphamide 350-500 mg/m²). ʻO nā ʻike koʻikoʻi mai a hiki i ʻehā mahina o ka hahai ʻana:

ʻAʻohe mea ʻawahia e kaupalena ana i ka lāʻau lapaʻau (DLTs), ≥Grade 3 cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), a i ʻole graft-versus-host disease (GVHD) i hōʻike ʻia. Ua hōʻike ka huahana i kahi ʻano palekana maikaʻi, me ka ʻole o nā mea maʻi i hoʻōki i ka lāʻau lapaʻau ma muli o nā hanana maikaʻi ʻole.

1) Ma waena o 5 mau maʻi i hoʻopau i ka loiloi pono mua ma ka Pule 4, 3 mau maʻi (60%) i loaʻa ka pane piha koʻikoʻi/pane piha (sCR/CR), a 4 mau maʻi (80%) i loaʻa ka maʻi koena liʻiliʻi (MRD)-negativityin ka iwi iwi. 2) Ua hōʻike nā ʻikepili pono mua mai 2 mau maʻi ma ka Lā 14 i ka hōʻemi ʻana i nā lesions hiki ke ana ʻia e ≥92% a me ≥65%, kēlā me kēia. 3) ʻAʻole i hiki i 1 maʻi ka manawa loiloi pono i kuhikuhi ʻia e ka protocol.

Ua noho nā poʻe maʻi sCR/CR a pau i nā pane e hoʻomau nei, me ka mea maʻi mua i hoʻopau i ka hahai ʻana o ʻehā mahina.

Ma muli o ka ʻikepili palekana mua a me ka pono, ua hōʻike ʻo CT0596 i ka hoʻomanawanui maikaʻi a me ka hoʻoikaika ʻana i nā hōʻailona pono i nā maʻi R/R MM ma nā pae mahele āpau i wehewehe mua ʻia, me ka hoʻonui ʻia ʻana o CAR-T i ʻike ʻia. Pono kēia mau ʻike i ka noiʻi hou ʻana ʻaʻole wale ma R/R MM, akā, i nā maʻi ʻino cell plasma ʻē aʻe a me nā maʻi autoimmune i hoʻopili ʻia e nā cell plasma autoreactive.

I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.

Helu Kelepona：4008803716

Email：myimmnet@163.com